Point72 Asset Management
CBAY

Point72 Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

Point72 Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-200,000
Closed -$1.43M – 1540
2019
Q2 		$1.43M Buy
+200,000
New +$2.26M 0.01% 719

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Point72 Asset Management's CBAY Position: Q1 2024 in Review

Point72 Asset Management sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 2,573,700 shares — an estimated $60.8M sold.

Point72 Asset Management first reported a position in CBAY in Q4 2014 and held it in 16 quarters. The position peaked at $60.8M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • Point72 Asset Management reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Point72 Asset Management sold 2,573,700 Cymabay Therapeutics shares in Q1 2024, an estimated $60.8M.
  • Point72 Asset Management first reported a position in Cymabay Therapeutics in Q4 2014 and held it in 16 quarters.
  • Point72 Asset Management's Cymabay Therapeutics position peaked at $60.8M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on Point72 Asset Management's 13F filing for Q1 2024, filed 15 May 2024.